This activity is intended for oncologists and nurses who treat patients with metastatic colorectal cancer.
This case-based live activity will cover the diagnosis, treatment and management of patients with Metastatic Colorectal Cancer.
Disclosure Of Unlabeled Use:
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, Drs. Ramalingam and Socinski may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Method Of Participation:
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the post-test and activity evaluation
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- All non-physician participants who successfully complete the post-test and evaluation will receive a certificate of participation.
- All nurses will receive a CNE certificate.
For CME questions, please contact: Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
Course Viewing Requirements:
RELEASE DATE: April 30, 2014
EXPIRATION DATE: April 29, 2015
Estimated Time to Complete This Educational Activity: 60 minutes
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.
Sponsored by Med Learning Group.
This activity was co-provided by Ultimate Medical Academy/CCM.
Supported by an Educational Grant from Bayer HealthCare.
Copyright 2014 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
Credit Designation:Med Learning Group designates this enduring web activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Jeffrey A. Meyerhardt, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Dana Farber Cancer Institute
M. Susan Burke, MD, FACP
Clinical Assistant Professor, Internal Medicine
Thomas Jefferson University Medical School
Senior Advisor, Internal Medicine Clinical Care Center
Lankenau Medical Center
CCM/UMA Lead Nurse Planner:
Margaret Governo, EdD, APRN BC
CCM Lead Nurse Planner
Ultimate Medical Academy
- Critically evaluate current clinical trial evidence supporting the use of targeted and chemotherapeutic approaches, and their combinations, in the management of mCRC across multiple lines of treatment
- Explain which factors driving patients segmentation (prognostic and predictive biomarkers, comorbidities, patients
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Course Chair - - Dr. Meyerhardt has no financial relationships to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, Vice President of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Flavia Piazza, VP, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Sarah Taegder, Director of Accounts for Med Learning Group has nothing to disclose.